Proteolysis-targeting chimera (PROTAC) and other targeted protein degradation (TPD ... However, the power of PROTACs lies in the engagement of E3 ligases, and currently, less than two percent of the ...

Shenzhen Zhongge Biotechnology Co. Ltd. has identified proteolysis targeting chimera (PROTAC) compounds comprising an E3 ubiquitin ligase binding moiety covalently linked to an interleukin-1 ...

Katalytic Therapeutics Inc. has divulged proteolysis targeting chimera (PROTAC) compounds comprising an E3 ubiquitin ligase binding moiety covalently linked to a phosphodiesterase PDE4-targeting ...

Representatives from four leading companies highlight emerging basic and clinical research that drives renewed optimism.

Successful research in targeted protein degradation depends not only on measurements at high sensitivity, speed and precision ...

A PROTAC is a heterobifunctional molecule that can bind both a target protein and an E3 ubiquitin ligase to facilitate the formation of a ternary complex, leading to ubiquitination and ultimate ...

CUL2 ZYG11B known as the substrate receptor of cullin-2 RING E3 ligase, is bound by SARS-CoV ... and offers valuable insights for optimizing PROTAC-based drug design based on NTH CUL2 ZYG11B ...

Our group's research efforts aim to uncover novel cancer treatments and centre around three main themes: PROTAC, Molecular Glue Degraders, and novel E3 ligases. My earlier research in PROTAC ...

Yang et al. developed a proteolysis-targeting chimera (PROTAC) 753b, which targets BCL-xL and BCL-2 to the E3 ubiquitin ligase VHL, and showed that it removed senescent cells specifically from the ...